COMPEL
10 evidence topics · 3 sources
Objective
Location and study date
Geographic scope
Study design
Allocation and masking
Eligibility criteria
Progression pattern required for enrollment
Treatment
Experimental and control oral treatments
Study outcomes
Rationale for using investigator-assessed progression-free survival as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized participants per arm
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Overall survival hazard ratio: 95% confidence interval
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
There were 49 participants per arm, and eligibility required non-CNS progression. The OS hazard-ratio confidence interval included 1, so the numerical median OS difference does not establish an OS benefit. This study does not directly compare osimertinib continuation with ivonescimab.